Literature DB >> 17965536

Inhibitory effect of the phosphoinositide 3-kinase inhibitor LY294002 on muscarinic acetylcholine receptor-induced calcium entry in PC12h cells.

Mitsuhiro Morita1, Kotaro Yoshizaki, Akira Nakane, Yoshihisa Kudo.   

Abstract

Phosphoinositide-3 kinase (PI3K) and phospholipase C (PLC) utilize the same phosphoinositides as substrates to produce different signaling molecules. These enzymes are activated by a similar set of cell signaling mechanisms, i.e., tyrosine kinases and G proteins, and affect common cell functions, including proliferation, motility, and intracellular trafficking. Despite these similarities, the interplay between these enzymes is not well understood. To address this issue, the effects of the PI3K inhibitor LY294002 on carbachol-induced calcium increase in PC12h cells were examined. As carbachol stimulates both Gq- and Gi-coupled muscarinic acetylcholine receptors (mAChRs), PI3K and PLC are activated simultaneously in this protocol. LY294002 was found to reduce the carbachol-induced calcium increase, and the reduction was attributed to suppression of calcium entry. As LY294002 did not affect either carbachol-induced calcium release or calcium entry induced by calcium store depletion, this agent was found to suppress calcium entry directly activated by mAChRs. Although PI3K was supposed to compete for substrates with PLC, the PI3K inhibitor did not enhance PLC-dependent cellular responses. As LY294002 was still effective by treating cells after carbachol stimulation, it is likely that this agent blocks the calcium entry channels directly.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965536     DOI: 10.1254/jphs.fp0070643

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  1 in total

1.  Signaling mechanisms mediating muscarinic enhancement of GABAergic synaptic transmission in the spinal cord.

Authors:  H-M Zhang; S-R Chen; Y-Q Cai; T E Richardson; L C Driver; G Lopez-Berestein; H-L Pan
Journal:  Neuroscience       Date:  2008-12-07       Impact factor: 3.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.